Granted Patent
B2
US 12,220,484 · App. 17/495,104 · Granted Feb 11, 2025
Stable formulations of lipids and liposomes
Assignee:
BioNTech SE
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.
Claims (32)
1. An aqueous liposome dispersion comprising:
liposomes comprising 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) and at least one cationic lipid selected from the group consisting of 1,2-di-O-octadecenyl-3-trimethylammoniumpropane (DOTMA) and 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), and
at least one pH adjusting agent comprising an acid or an acidic buffer;
wherein:
a molar ratio of the at least one cationic lipid to DOPE is from about 1:4 to about 4:1; and
the pH of the aqueous liposome dispersion is from about 2 to about 5.5.
2. The aqueous liposome dispersion of claim 1 , wherein the liposomes have an average diameter from about 200 nm to about 600 nm.
3. The aqueous liposome dispersion of claim 1 , wherein the at least one pH adjusting agent comprises an acid.
4. The aqueous liposome dispersion of claim 3 , wherein the acid is acetic acid.
5. The aqueous liposome dispersion of claim 1 , wherein the at least one pH adjusting agent comprises an acidic buffer.
6. The aqueous liposome dispersion of claim 5 , wherein the acidic buffer is acetate buffer.
7. The aqueous liposome dispersion of claim 1 , wherein the at least one pH adjusting agent is associated with the liposomes.
8. The aqueous liposome dispersion of claim 1 , wherein the cationic lipid is DOTMA.
9. The aqueous liposome dispersion of claim 1 , wherein the cationic lipid is DOTAP.
10. The aqueous liposome dispersion of claim 1 , wherein the aqueous liposome dispersion has a pH that is about 3 to about 4.5.
11. The aqueous liposome dispersion of claim 1 , wherein the aqueous liposome dispersion is characterized in that the hydrolysis rate of DOPE in the liposomes is reduced as compared to its hydrolysis rate at a pH between about 6 and 7.
12. The aqueous liposome dispersion of claim 1 , wherein the aqueous liposome dispersion is characterized in that the hydrolysis rate of DOTAP in the liposomes is reduced as compared to its hydrolysis rate at a pH between about 6 and 7.
13. A kit comprising:
(i) a first container comprising an aqueous liposome dispersion, wherein the aqueous liposome dispersion comprises:
liposomes comprising 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phospho-ethanolamine (DOPE) and at least one cationic lipid selected from the group consisting of 1,2-di-Ooctadecenyl-3-trimethylammoniumpropane (DOTMA) and 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), and
at least one pH adjusting agent comprising an acid or an acidic buffer;
wherein:
a molar ratio of the at least one cationic lipid to DOPE is from about 1:4 to about 4:1; and
the pH of the aqueous liposome dispersion is from about 2 to about 5.5; and
(ii) a second container comprising a nucleic acid in a buffered solution having a pH from about 6 to about 8.
14. The kit of claim 13 , wherein the at least one pH adjusting agent comprises an acidic buffer.
15. The kit of claim 14 , wherein the acidic buffer is acetate buffer.
16. The kit of claim 13 , wherein the cationic lipid is DOTMA.
17. The kit of claim 13 , wherein the cationic lipid is DOTAP.
18. The kit of claim 13 , wherein the nucleic acid is RNA.
19. The kit of claim 18 , wherein the RNA is messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), small inhibitory RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), antisense RNA, immunostimulating RNA (isRNA), or RNA aptamers.
20. The kit of claim 19 , wherein the RNA is mRNA.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 22, 2021
From: HAAS, HEINRICH; ESPARZA BORQUEZ, ISAAC HERNAN
To: BIONTECH RNA PHARMACEUTICALS GMBH
Reel/Frame 058180/0130 →
MERGER AND CHANGE OF NAME
Recorded Nov 19, 2021
From: BIONTECH RNA PHARMACEUTICALS GMBH; BIONTECH SE
To: BIONTECH SE
Reel/Frame 058215/0001 →
Continuity (2)
Continuation
15510973
References Cited (252)
US 4897355A
· Eppstein et al.
· 1990
[cited by applicant]
US 5264618A
· Felgner et al.
· 1993
[cited by applicant]
US 5703055A
· Felgner et al.
· 1997
[cited by applicant]
US 5965542A
· Wasan et al.
· 1999
[cited by applicant]
US 6034137A
· Belloni et al.
· 2000
[cited by applicant]
US 6251399B1
· Diamond et al.
· 2001
[cited by applicant]
US 6372498B2
· Newman et al.
· 2002
[cited by applicant]
US 6413544B1
· Smyth-Templeton et al.
· 2002
[cited by applicant]
US 6472176B2
· Kovesdi et al.
· 2002
[cited by applicant]
US 6500641B1
· Chen et al.
· 2002
[cited by applicant]
US 6586410B1
· Wheeler et al.
· 2003
[cited by applicant]
US 7303881B2
· Huang et al.
· 2007
[cited by applicant]
US 7462354B2
· Sette et al.
· 2008
[cited by applicant]
US 7790696B2
· Gregoriadis
· 2010
[cited by applicant]
US 8140270B2
· Kingsmore et al.
· 2012
[cited by applicant]
US 8217016B2
· Hoerr et al.
· 2012
[cited by applicant]
US 8349558B2
· Fatho et al.
· 2013
[cited by applicant]
US 8703142B2
· Diamond et al.
· 2014
[cited by applicant]
US 8853283B2
· Platscher et al.
· 2014
[cited by applicant]
US 8877206B2
· Chen et al.
· 2014
[cited by applicant]
US 9115402B2
· Hacohen et al.
· 2015
[cited by applicant]
US 9707299B2
· Muro-Galindo et al.
· 2017
[cited by applicant]
US 20060147513A1
· Papahadjopoulos et al.
· 2006
[cited by applicant]
US 20060159737A1
· Panzner et al.
· 2006
[cited by applicant]
US 20060257465A1
· Maurer et al.
· 2006
[cited by applicant]
US 20070025968A1
· Van Der Burg et al.
· 2007
[cited by applicant]
US 20070207194A1
· Grayburn et al.
· 2007
[cited by applicant]
US 20120021042A1
· Panzner et al.
· 2012
[cited by applicant]
US 20120237975A1
· Schrum et al.
· 2012
[cited by applicant]
US 20130028962A1
· Zhang et al.
· 2013
[cited by applicant]
US 20130123481A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130156849A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130237593A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130244279A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245106A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130245107A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20130255281A1
· Bray
· 2013
[cited by applicant]
US 20130266640A1
· de Fougerolles et al.
· 2013
[cited by applicant]
US 20140010861A1
· Bancel et al.
· 2014
[cited by applicant]
US 20150030576A1
· Bancel
· 2015
[cited by applicant]
US 20150167017A1
· Roy et al.
· 2015
[cited by applicant]
US 20150252372A1
· Chang et al.
· 2015
[cited by applicant]
US 20160002667A1
· Kaufman et al.
· 2016
[cited by applicant]
CA 2271325A1
· 1998
[cited by applicant]
CA 2816925
· 2011
[cited by examiner]
CN 102858153A
· 2013
[cited by applicant]
CN 103906503A
· 2014
[cited by applicant]
EP 0839912A1
· 1998
[cited by applicant]
EP 1242108A1
· 2002
[cited by applicant]
EP 2569633A2
· 2013
[cited by applicant]
JP 2005535730A
· 2005
[cited by applicant]
JP 4975964
· 2012
[cited by examiner]
WO WO1994023031A1
· 1994
[cited by applicant]
WO WO9535094A1
· 1995
[cited by applicant]
WO WO1998014464A1
· 1998
[cited by applicant]
WO WO1999024566A1
· 1999
[cited by applicant]
WO WO1999052503A2
· 1999
[cited by applicant]
WO WO200020029A1
· 2000
[cited by applicant]
WO WO2000067761A1
· 2000
[cited by applicant]
WO WO2001047959A2
· 2001
[cited by applicant]
WO WO2001093902A2
· 2001
[cited by applicant]
WO WO2002048377A2
· 2002
[cited by applicant]
WO WO2002083714A2
· 2002
[cited by applicant]
WO WO02098443A2
· 2002
[cited by applicant]
WO WO2003051401A2
· 2003
[cited by applicant]
WO WO2003068257A1
· 2003
[cited by applicant]
WO WO2003106692A2
· 2003
[cited by applicant]
WO WO2004002453A1
· 2004
[cited by applicant]
WO WO2004002468A1
· 2004
[cited by applicant]
WO WO2004004743A1
· 2004
[cited by applicant]
WO WO2005030250A2
· 2005
[cited by applicant]
WO WO2005039533A1
· 2005
[cited by applicant]
WO WO2005040816A1
· 2005
[cited by applicant]
WO WO2005110338A2
· 2005
[cited by applicant]
WO WO2006121168A1
· 2006
[cited by applicant]
WO WO2007024708A2
· 2007
[cited by applicant]
WO WO2007025760A2
· 2007
[cited by applicant]
WO WO2007031222A2
· 2007
[cited by applicant]
WO WO2007101227A2
· 2007
[cited by applicant]
WO WO2008080468A1
· 2008
[cited by applicant]
WO WO2008083174A2
· 2008
[cited by applicant]
WO WO2008085562A2
· 2008
[cited by applicant]
WO WO2008116078A2
· 2008
[cited by applicant]
WO WO2008147526A1
· 2008
[cited by applicant]
WO WO2008156712A1
· 2008
[cited by applicant]
WO WO2009053041A2
· 2009
[cited by applicant]
WO WO2009118296A2
· 2009
[cited by applicant]
WO WO2009129227A1
· 2009
[cited by applicant]
WO WO2010066418A1
· 2010
[cited by applicant]
WO WO2010105209A1
· 2010
[cited by applicant]
WO WO2011012316A2
· 2011
[cited by applicant]
WO WO2011143656A2
· 2011
[cited by applicant]
WO WO2012045075A1
· 2012
[cited by applicant]
WO WO2012045082A2
· 2012
[cited by applicant]
WO WO2012135805A2
· 2012
[cited by applicant]
WO WO2012159729A1
· 2012
[cited by applicant]
WO WO2013040142A2
· 2013
[cited by applicant]
WO WO2013052523A1
· 2013
[cited by applicant]
WO WO2013064911A2
· 2013
[cited by applicant]
WO WO2013090648A1
· 2013
[cited by applicant]
WO WO2013124701A2
· 2013
[cited by applicant]
WO WO2013151663A1
· 2013
[cited by applicant]
WO WO2013151664A1
· 2013
[cited by applicant]
WO WO2013151665A2
· 2013
[cited by applicant]
WO WO2013151672A2
· 2013
[cited by applicant]
WO WO2014012051A1
· 2014
[cited by applicant]
WO WO2014071219A1
· 2014
[cited by applicant]
WO WO2014093924A1
· 2014
[cited by applicant]
WO WO2014144039A1
· 2014
[cited by applicant]
WO WO2014144711A1
· 2014
[cited by applicant]
WO WO2014144767A1
· 2014
[cited by applicant]
WO WO2014152027A1
· 2014
[cited by applicant]
WO WO2014152030A1
· 2014
[cited by applicant]
WO WO2014152031A1
· 2014
[cited by applicant]
WO WO2014152211A1
· 2014
[cited by applicant]
WO WO2014159813A1
· 2014
[cited by applicant]
WO WO2014160243A1
· 2014
[cited by applicant]
WO WO2014164253A1
· 2014
[cited by applicant]
WO WO2014168874A2
· 2014
[cited by applicant]
WO WO2015014375A1
· 2015
[cited by applicant]
WO WO2015034925A1
· 2015
[cited by applicant]
WO WO2015034928A1
· 2015
[cited by applicant]
WO WO2015038892A1
· 2015
[cited by applicant]
WO WO2015043613A1
· 2015
[cited by applicant]
WO WO2015051169A2
· 2015
[cited by applicant]
WO WO2015051173A2
· 2015
[cited by applicant]
WO WO2015058780A1
· 2015
[cited by applicant]
WO WO2015085318A2
· 2015
[cited by applicant]
WO WO2015089511A2
· 2015
[cited by applicant]
WO WO2015117620A1
· 2015
[cited by applicant]
WO WO2015164674A1
· 2015
[cited by applicant]
WO WO2015172843A1
· 2015
[cited by applicant]
WO WO2016045732A1
· 2016
[cited by applicant]
WO WO2016062323A1
· 2016
[cited by applicant]
WO WO2016091391A1
· 2016
[cited by applicant]
WO WO2016107877A1
· 2016
[cited by applicant]
WO WO2016155809A1
· 2016
[cited by applicant]
Hui, S. et al., The Role of Helper Lipids in Cationic Liposome-Mediated Gene Transfer, Biophysical Journal, 71:590-599 (1996).
[cited by applicant]
Ozpolat, B. et al., Liposomal siRNA nanocarriers for cancer therapy, Advanced Drug Delivery Reviews, 66:110-116 (2014).
[cited by applicant]
Nov. 30, 2018—(EP) Office Action—App. 15763367.8.
[cited by applicant]
Apr. 2, 2019—(JP) Office Action—App. 2017-516418.
[cited by applicant]
Jan. 21, 2019—(SG) Written Opinion—Application No. 11201702182Y.
[cited by applicant]
Agrawal et al., Trend in Biotechnology, 14(10): 376-387, 1996.
[cited by applicant]
Bei et al., J Immunother., 21(3):159-69 (1998).
[cited by applicant]
Boczkowski et al., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J Exp. Med., 184:465-472 (1996).
[cited by applicant]
Bowerman, NA., Engineering the binding properties of the T cell receptor: peptide: MHC ternary complex that governs T cell activity, Mol. Immun., 46:3000-3008 (2009).
[cited by applicant]
Brickner et al. J Exp. Med 193(2) 195-205 (2001).
[cited by applicant]
Chen et al., An overview of liposome lyophilization and its future potential, J Controlled Release, 142(3):299-311 (2010).
[cited by applicant]
Conry et al., Characterization of a messenger RNA polynucleotide vaccine vector, Cancer Res,. 55:1397-1400 (1995).
[cited by applicant]
Conry et al., Immune response to a carcinoembryonic antigen polynucleotide vaccine, Cancer Res., 54:1164-1168 (1994).
[cited by applicant]
Coulie et al., A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. USA, 92:7976-7980 (1995).
[cited by applicant]
De La Torre, L. G et al., The synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE liposomes and DOTAP/DOPE lipoplexes, Colloids and Surfaces B: Biointerfaces, 73:175-1…
[cited by applicant]
Del Val et al., Cell, 66(6):1145-1153 (1991).
[cited by applicant]
Dengjel, J et al. Glycan side chains on naturally presented MHC class II ligands J Mass Spectrom, 2005.
[cited by applicant]
Ding et al. Genome remodeling in a basal-like breast cancer metastasis and xenograft Nature, 464: 999-1005, 2010.
[cited by applicant]
Dolgin, Nature 522:26.
[cited by applicant]
Dolgin, The Billion-Dollar Biotech, Nature, 522:26-28, Jun. 4, 2015.
[cited by applicant]
Fenske et al., Entrapment of small molecules and nucleic acid-based drugs in liposomes, Methods Enzymol, 391:7-40 (2005).
[cited by applicant]
Fritsch, E. F. et al. HLA-Binding Properties of Tumor Neoepitopes in Humans Cancer Immunology Research, 2: 522-529, 2014.
[cited by applicant]
Gnirke, A. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing Nat. Biotechnol, 2009.
[cited by applicant]
Goya, R. et al. SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors, Bioinformatics Bioinformatics, 26: 730-736, 2010.
[cited by applicant]
Grit et al., Chemical stability of liposomes: implications for their physical stability, Chemistry and Physics of Lipids, 64:3-18 (1993).
[cited by applicant]
Grit et al., Hydrolysis of phosphatidylcholine in aqueous liposome dispersions, International Journal of Pharmaceutics, 50:1-6 (1989).
[cited by applicant]
Grit, M et al., Hydrolysis of Saturated Soybean Phosphatidylcholine in Aqueous Liposome Dispersions, Journal of Pharmaceutical Sciences, 82(4): 362-366 (1993).
[cited by applicant]
Gryaznov et al., Biochim. Biophys. Acta, 1489: 131-140, 1999.
[cited by applicant]
Guyre et al., Cancer Immunother, 45:146-148 (1997).
[cited by applicant]
Hacohen Decl. dated Feb. 16, 2014 filed in U.S. Appl. No. 13/108,610, 10 pages.
[cited by applicant]
Hoerr et al., In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies, Eur. J. Immunol., 30:1-7 (2000).
[cited by applicant]
How Long Can I Store Liposomes?, Avanti Polar Lipids, retreived on Jul. 19, 2020 from https://avantilipids.com/tech-support/faqs/liposomes-shelf-life, 2 pages.
[cited by applicant]
How Should I Store My Liposomes?, Avanti Polar Lipids, retreived on Jul. 19, 2020 from http://avantilipids.com/tech-support/faqs/liposome-storage, 2 pages.
[cited by applicant]
Hydrolysis and Oxidation of Liposomes, Encapsula NanoSciences, retreived on Aug. 21, 2020 from https://encapsula.com/hydrolysis-and-oxidation-of-liposomes/, 5 pages.
[cited by applicant]
International Preliminary Report on Patentability Chapter I, Dated Mar. 28, 2017, Filed in relation to PCT Application No. PCT/EP2014/070503, Filed Sep. 25, 2014, Entitled Stable Formulations of Lipids and Liposomes, By…
[cited by applicant]
International Preliminary Report on Patentability Chapter I, Dated Mar. 28, 2017, Filed in relation to PCT Application No. PCT/EP2015/071344, Filed Sep. 17, 2015, Entitled Stable Formulations of Lipids and Liposomes, By…
[cited by applicant]
International Search Report (ISR), Dated Dec. 14, 2015, Filed in relation to PCT Application No. PCT/EP2015/071344, Filed Sep. 17, 2015, Entitled “Stable Formulations of Lipids and Liposomes,” By Applicant “BioNTech RNA…
[cited by applicant]
International Search Report (ISR), Dated Jul. 8, 2015, Filed in relation to PCT Application No. PCT/EP2014/070503, Filed Sep. 25, 2014, Entitled “Stable Formulations of Lipids and Liposomes,” Bv Aoolicant “BioNTech RNA …
[cited by applicant]
Johanning et al., Nucleic Acids Res., 23(9):1495-1501 (1995).
[cited by applicant]
Kenter, G. G. et al. Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 sequences of High-risk human papillomavirus 16 in End-stage cervical cancer patients shows low toxicity and robust immunogen…
[cited by applicant]
Keogh, E. et al. Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A*0201-Binding Affinity, J. Immunol. 167: 787-796, 2001.
[cited by applicant]
Lemmel, Claudia et al., Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling Nat Biotechnol, 2004.
[cited by applicant]
Lennerz et al., The response of autologous T cells to a human melanoma is dominated by mutated heoantigens, Proc. Natl. Acad. Sci. USA, 102:16013-16018 (2005).
[cited by applicant]
Ley et al., DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome, Nature, 456:66-72 (2008).
[cited by applicant]
Li et al., Cancer Genome Sequencing and Its Implications for Personalized Cancer Vaccine, Cancer, 3:1191-4211 (2011).
[cited by applicant]
Maksyutov and Zagrebelnaya, ADEPT: a computer program for prediction of protein antigenic determinants, Comput. Appl. Biosci., 9:291-297 (1993).
[cited by applicant]
Mandelboim et al., Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides, Nature Medicine, 1:1179-1183 (1995).
[cited by applicant]
Mardis, ER., Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome, New England J. Med., 361:1058-1066 (2009).
[cited by applicant]
Margulies, Marcel et al., Genome Sequencing in Open Microfabricated High Density Picoliter Reactors Nature, 2005.
[cited by applicant]
Martinon et al., Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome- entrapped mRNA, Eur. J. Immunol, 23:1719-1722 (1993).
[cited by applicant]
Mayer et al., Anticancer Research 25:3917-3924 (2005).
[cited by applicant]
Mayer et al., Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients, Biochim Biophys Acta, 1025(2):143-51 (1990).
[cited by applicant]
Meyerson, M. et al. Advances in understanding cancer genomes through second-generation sequencing Nature Rev. Genetics. 11:685-695, 2010.
[cited by applicant]
Monach et al., A unique tumor antigen produced by a single amino acid substitution, Immunity, 2:45-59 (1995).
[cited by applicant]
Mortazavi, Mapping and quantifying mammalian transcriptomes by RNA-Seq, Nature Methods, 5:621-628 (2008).
[cited by applicant]
Parker et al., J. Immunol., 152:163-175 (1994).
[cited by applicant]
Parkhurst, MR. et al. Improved Induction of Melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 157: 2549-2548, 1996.
[cited by applicant]
Parmiani, G et al., Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials, The Journal of mmunology, 178:1975-1979 (2007).
[cited by applicant]
Perissi et al., Electron Spin Resonance and Differential Scanning Calorimetry as Combined Tools for the Study of iposomes in the Presence of Long Chain Nitroxides, 106 J. of Phys. Chem. B 10468 (2002).
[cited by applicant]
Pfohl et al., Biological Polyelectrolyte Complexes in Solution and Confined on Patterned Surfaces, 198-200 Colloids & Surfaces A: Physicochemical and Eng. Aspects 613 (2002).
[cited by applicant]
Pilla, L. et al. Multipeptide vaccination in cancer patients Expert Opinion on Biological Therapy, 9: 1043-1055, 2009.
[cited by applicant]
Pleasance, E. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463: 184-190, 2010.
[cited by applicant]
Pleasance, E. et al., A comprehensive catalogue of somatic mutations from a human cancer genome, Nature, 463:191-196 (2010).
[cited by applicant]
U.S. Appl. No. 61/334,866, filed May 14, 2010.
[cited by applicant]
Rammansee, Chapter 50: Cancer Vaccines: Some Basic Considerations, Genomic and Personalized Medicine, Hungtington and Ginsburg. E-published on Nov. 11, 2008.
[cited by applicant]
Rammensee et al., Immunogenentics, 50:213-219 (1999).
[cited by applicant]
Rammensee et al., Toward patient-specific tumor antigen selection for vaccination, Immunol. Rev, 188:164-176 (2002).
[cited by applicant]
Rammensee, Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer, Immunol Cell Biol., 84(3):290-4 (2006).
[cited by applicant]
Rao, Epitope-based vaccines: One step at a time, Proc. Indian natn. Sci. Acad., B60:419-424 (1994).
[cited by applicant]
Remaut, K et al., Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes, Journal of Controlled Release, 115:335-343 (2006).
[cited by applicant]
Ressing, M et al. Human CTL epitopes encoded by human papillomavirus types 16E6. J Immunol. 154:5934-5943, 1995.
[cited by applicant]
Saenz-Badillos et al., RNA as a tumor vaccine: a review of the literature, Exp Dermatol., 10(3):143-54 (2001).
[cited by applicant]
Segal et al., Epitope landscape in breast and colorectal cancer, Cancer Res. 68: 889-892 (2008).
[cited by applicant]
Sensi and Aanichini, Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets forT cell-mediated Patient-Specific Immunotherapy, Clin. Cancer Res., 12(17), 5023 (2006).
[cited by applicant]
Sette, A. et al. Peptide Binding to the Most Frequent HLA-A Class I Alleles Measured by Quantitative Molecular Binding Assays Mol. Immunol. 31: 813-822, 1994.
[cited by applicant]
Sette, A. et al. The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T cell Epitopes. J Immunol. 153: 5586-5592, 1994.
[cited by applicant]
Shah et al., Mutation of FOXL2 in granulosa-cell tumors of the ovary, N. Eng. J. Med., 360:2719-2729 (2009).
[cited by applicant]
Sjoblom et al., The consensus coding sequences of human breast and colorectal cancers, Science 314:268-274 (2006).
[cited by applicant]
Stark et al., Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure, European J Pharm. Sci, 41(3-4):546-555 (2010).
[cited by applicant]
Stephens et al., A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer, Nature Genetics, 37:590-592 (2005).
[cited by applicant]
Thomson et al., J. Virology, 72(3):2246-2252 (1998).
[cited by applicant]
Toes et al., Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding 9 multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion, Proc. Natl. Acad. Sci. …
[cited by applicant]
UniProtKB—P36888 (FLT3_HUMAN), last sequence update: Aug. 21, 2007.
[cited by applicant]
UniProtKB—Q5SW79 (CE170_HUMAN), last sequence update: Dec. 21, 2004.
[cited by applicant]
UniProtKB—Q9NVD7 (Parva_Human), last sequence update: Oct. 1, 2000.
[cited by applicant]
UniProtKB, “Print-outs from the UniProtKB database concerning the CEP170, Parva and FLT3 genes.”
[cited by applicant]
Van der Bruggen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254:1643-1647 (1991).
[cited by applicant]
Van Laere, AS, et al. A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig, Nature, 425(6960):832-836 (2003).
[cited by applicant]
Van Winden, E. et al., Strategies for large scale production and optimized stability of pharmaceutical liposomes developed for parenteral use, Lasic and Papahadjopoulous (eds,.), Medical Applications of Liposomes, 567-6…
[cited by applicant]
Van Winden, et al., Short term stability of freeze-dried, lyoprotected liposomes, J Controlled Release, 58(1):69-86 (1999).
[cited by applicant]
Vernooij et al., Chemical hydrolysis of DOT AP and DOPE in a liposomal environment, Journal of Controlled Release, 79:299-303 (2002).
[cited by applicant]
Weinschenk et al., Integrated functional genomics approach for the design of patient-individual antitumor vaccines, Cancer Res, 62:5818-5827 (2002).
[cited by applicant]
Wolff, et al., Direct gene transfer into mouse muscle in vivo, Science 247:1465-1468 (1990).
[cited by applicant]
Wood et al., The genomic landscapes of human breast and colorectal cancers, Science, 318:1108-1113 (2007).
[cited by applicant]
Wortzel et al., Multiple tumour-specific antigens expressed on a single tumour cell, Nature, 304:165-167 (1983).
[cited by applicant]
Written Opinion issued in related Singapore Application No. 11201702182Y, dated Feb. 12, 2018.
[cited by applicant]
Written Opinion of the International Search Authority, Dated Dec. 14, 2015, Filed in relation to PCT Application No. PCT/EP2015/071344, Filed Sep. 17, 2015, Entitled Stable Formulations of Lipids and Liposomes, By Appli…
[cited by applicant]
Written Opinion of the International Search Authority, Dated Jul. 8, 2015, Filed in relation to PCT Application No. PCT/EP2014/070503, Filed Sep. 25, 2014, Entitled “Stable Formulations of Lipids and Liposomes,” By Appl…
[cited by applicant]
Zhou et al., Hum. Gene Ther., 10(16):2719-24, 1999.
[cited by applicant]
Zuidam et al., Chemical Hydrolysis of Phospholipids, Journal of Pharmaceutical Sciences, 84(9) Sep. 1995.
[cited by applicant]